Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CD4 Lymphocyte Count”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,621 records · Page 90Linked to original sources

[Giant anovulvar condyloma acuminata revealing hiv-1 seropositivity in a Centrafrican patient].

As a general rule, genital condylomas present as localized lesions and large masses of warts are observed only during pregnancy. In this report we describe a giant anogenital condyloma in a non-pregnant 18-year-old Centrafrican woman. Soft papillomas completely covered the anterior and posterior perineum and obstructed the vagina. Clinical findings were suggestive of vulvar Buschke and Loewenstein tumor. The extent of the lesions and a history of unprotected relations with several sex partners raised suspicion of HIV infection which was subsequently confirmed. The CD4+ lymphocyte count was 540/min3. Surgical removal led to complete cure after healing of the surgical wound. Histological findings showed that the lesions were benign and ruled out malignant vulvar tumor. This case documents the link between florid genital condylomas and HIV infection with no change in immune status.

Adolescent↗

Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART).

This study assessed glucose tolerance, insulin sensitivity and lipid parameters in HIV-infected patients presenting with lipodystrophy during HAART including protease inhibitors. Fourteen consecutive patients from Rothschild Hospital treated with HAART and presenting with marked facial lipoatrophy were evaluated. A 75 g oral glucose tolerance test (OGTT) with measurement of plasma glucose, insulin, proinsulin and free fatty acids at T0, 30, 60, 90 and 120 min was performed. Lipid parameters (triglycerides, cholesterol, apolipoproteins A1 and B) were studied as well as nutritional and inflammatory markers (albumin, prealbumin, transferrin, haptoglobin, orosomucoid, C-reactive protein), endocrine and cytokine parameters (thyrotropin, cortisol, leptin, interleukin-6), HIV viral load and CD4-lymphocyte count. These patients were compared with 20 non-lipodystrophic protease inhibitor-treated patients. The measurements performed during OGTT showed that among the 14 lipodystrophic patients, 11 (79%) presented with diabetes (5 patients) or normal glucose tolerance but with insulin resistance (6 patients). This frequency was strikingly different in the group of nonlipodystrophic patients, which included only 4 (20%) presenting with diabetes (1 patient), or impaired glucose tolerance (2 patients), or normal glucose tolerance but with insulin resistance (1 patient). Hypertriglyceridaemia was present in 11 lipodystrophic (79%) versus 7 nonlipodystrophic patients (35%). Nutritional and endocrine measurements were normal. An abnormal processing of proinsulin to insulin was excluded. Thus, lipodystrophy during HAART was associated with diabetes, insulin resistance and hypertriglyceridaemia. Diabetes, diagnosed by basal and/or 120 min-OGTT glycaemia, seems more frequent than previously described. The therapeutic consequences of these results deserve evaluation in clinical trials.

Adult↗

Pattern of defervescence in response to anti-tuberculosis therapy in patients with extrapulmonary tuberculosis and advanced human immunodeficiency virus infection.

The pattern of fever response to empiric anti-tuberculosis therapy in patients with tuberculosis (TB) and human immunodeficiency virus (HIV) infection, and the relationship between fever response patterns and anti-TB drug susceptibility profiles of Mycobacterium tuberculosis isolates are rarely described. In this study, we evaluated the fever responses to a four-drug anti-TB regimen in 26 HIV-infected patients with culture-proven extrapulmonary TB, and compared the results with those in 12 patients with disseminated Mycobacterium avium complex (DMAC) infection treated with a clarithromycin-containing regimen. The CD4 lymphocyte counts did not differ significantly between TB and DMAC patients (26 x 10(6)/L in TB patients vs 5 x 10(6)/L in DMAC patients). Drug susceptibility data were available for 22 patients with TB. Most TB patients had rapid defervescence after initiation of anti-TB therapy. Fever resolved within 1 week in 85% (22/26) of patients, including three of six (50%) with multidrug-resistant (MDR) TB. The median duration of fever in patients with drug-susceptible TB was similar to that in patients with drug-resistant TB (3 vs 4 days, p = 0.33). However, patients with MDR-TB were more likely than those with non-MDR TB to have fevers lasting longer than 1 week after initiating anti-TB therapy (3/6 vs 1/16, p = 0.046). Only 17% (2/12) of the patients with DMAC infection became afebrile within 1 week of beginning anti-MAC therapy (p < 0.001 vs those with TB). Our observations suggest that in HIV-infected patients with advanced immunosuppression, anti-TB regimens achieve significantly faster defervescence in TB patients than do anti-MAC regimens in DMAC patients. Rapid defervescence in patients with TB does not necessarily indicate that TB isolates are not MDR strains.

AIDS-Related Opportunistic Infections↗

[Seroepidemiology of Bartonella henselae infection in HIV-infected patients].

BACKGROUND: Bartonella henselae infections are closely related to numerous clinical infections of growing interest in Spain. Since immunosuppressed patients are a potential risk group for infection by this bacteria, the aim of the present was to study the seroepidemiology of B. henselae infection in a risk group (patients with HIV infection) and in a control group (donors). PATIENTS AND METHODS: In October, 1997, antibodies versus B. henselae were determined at different dilutions (cut off > or = 1:64) by immunofluorescence in 52 patients with HIV infection and 85 donors. An epidemiologic study included age, sex, smoking, alcohol intake, INVDA, HIV infection, AIDS stage, cutaneous anergy, CD4 lymphocyte count, antiretroviral treatment and chemoprophylaxis versus P. carinii. RESULTS: Nine of the patients with HIV infection (17.3%) and five donors (5.88%) presented titers > or = 1:64 with no significant differences (p = 0.06) (adjusted OR: 1.7; CI 95%: 0.34-8.54). Moreover, multiple logistic regression analysis did not show any risk or protection factor associated with B. henselae infection in patients with HIV infection. CONCLUSIONS: A high level of seroprevalence of antibodies versus B. henselae was observed in patients with HIV infection. No risk or protection factors associated with B. henselae infection in patients with HIV infection were found.

Adult↗

[The oxidative metabolic activity of the polymorphonuclear neutrophilic leukocytes in patients infected with the human immunodeficiency virus].

BACKGROUND: Contradictory results on oxidative burst activity in HIV infection have been reported in the literature. PATIENTS AND METHODS: Neutrophil oxidative metabolism was evaluated in 160 HIV-infected patients, by measuring the intracellular production of rhodamine. RESULTS: Neutrophil oxidative metabolism was decreased. This impairment was related to viral load, CD4+ lymphocyte counts, neutrophil counts and therapy. CONCLUSIONS: In HIV-infected patients, neutrophil oxidative metabolic activity decreases with disease progression. This may contribute to secondary opportunistic infections.

Adult↗

Pneumocystis carinii pneumonia.

Throughout the epidemic, Pneumocystis carinii pneumonia (PCP) has been the most common AIDS-defining opportunistic infection in the United States. With the widespread use of highly active antiretroviral therapy (HAART) and prophylaxis in patients known to be at risk, the incidence of PCP in patients with AIDS has declined dramatically. However, it is still seen regularly in patients with previously undiagnosed human immunodeficiency virus (HIV) infection, those who do not comply with prophylactic medications, and in occasional cases of failure of prophylaxis. Despite many years of study, our understanding of the biology, ecology, and pathogenesis of PCP is inadequate. Clinically, PCP in AIDS tends to be a less acute and milder illness than PCP in other types of immunocompromised hosts. Although the radiograph typically shows bilateral diffuse granular opacities, many other patterns are seen. Trimethoprim-sulfamethoxazole is the preferred drug for treating and preventing PCP, but toxicity limits its use. The choice of treatment is influenced by the severity of illness and relative toxicities of antipneumocystis agents. Adjunctive corticosteroid therapy is recommended for patients with moderate or severe disease. The success of HAART has prompted investigators to question whether prophylaxis against PCP and other opportunistic infections is necessary in patients who respond with a rise in CD4 lymphocyte counts and suppression of HIV replication.

AIDS-Related Opportunistic Infections↗

Diagnosing HIV-associated tuberculosis: reducing costs and diagnostic delay.

SETTING: University-affiliated hospital in South Africa. OBJECTIVE: To assess the time to diagnosis and the yield and laboratory cost of diagnostic procedures in human immunodeficiency virus (HIV) associated tuberculosis. DESIGN: Cohort study. PATIENTS: Adult HIV-infected patients with newly-diagnosed tuberculosis admitted over a 2-year period. RESULTS: A total of 141 admissions fulfilled the case definition. Sputum smear yield (43% overall) correlated strongly with chest radiograph appearance but not with CD4+ lymphocyte count. Sputum smear yield was approximately 40% per sample sent, resulting in a high cumulative yield when > or = three samples were sent. Smear of sputum or wide needle lymph node aspirates were the most cost-effective diagnostic methods. Significant diagnostic delay occurred in sputum smear-negative patients. Most patients with sputum smear-negative tuberculosis had either pleural effusions or lymphadenopathy. Lymph node biopsy had a high diagnostic yield even in patients with symmetrical nodes, but was under-utilised in this group. There was unnecessary expenditure on cultures, with many patients having several positive cultures. CONCLUSION: Repeated sputum smear examination produces a high cumulative yield in HIV-associated tuberculosis. Considerable savings in laboratory utilisation and bed occupancy would have been made if a streamlined diagnostic approach with greater use of lymph node aspirate and early pleural or lymph node biopsy had been followed.

Adult↗

The choice of HIV protease inhibitor: indinavir is currently the best option.

(1) Recent consensus recommendations agree that first-line treatment of HIV infection should consist of a three-drug regimen combining a protease inhibitor and two nucleoside reverse transcriptase inhibitors. Some recommendations specifically advise against using the current formulation of saquinavir, but none express a preference for one of the other three protease inhibitors currently marketed in France (indinavir, nelfinavir and ritonavir). (2) These HIV protease inhibitors have established efficacy on viral load and the CD4+ lymphocyte count. Saquinavir may have lower virological efficacy. (3) The clinical efficacy of three-drug regimens containing indinavir or saquinavir is well demonstrated in patients at an advanced stage of HIV disease. (4) The risk of viral resistance is not currently a factor in choosing a HIV protease inhibitors. (5) Several epidemiological studies have compared the risk of adverse effects on three-drug regimens including indinavir, ritonavir or saquinavir. In these studies saquinavir was the best-tolerated drug and ritonavir the worst-tolerated. (6) Ritonavir interacts with many drugs. The poor bioavailability of the current saquinavir formulation also leads to risk of interactions. (7) Treatment constraints differ from one protease inhibitor to another, and these must be taken into account case by case. (8) The daily cost of treatment is not currently an important factor in choosing among the various preparations. (9) Taking into account efficacy, adverse effects, interactions and treatment constraints, the combination of indinavir with two nucleoside reverse transcriptase inhibitors currently seems to be the best choice for the largest number of patients. (10) If problems of compliance arise, nelfinavir can be an alternative to indinavir. (11) In patients at an advanced stage of HIV disease who comply well with their treatment, saquinavir can also be an alternative to indinavir.

Clinical Trials as Topic↗

[Infective endocarditis].

Two different series of patients with Infectious Endocarditis (IE), hospitalized in the same ward of Curry Cabral Hospital in Lisbon, are presented and compared. The two series were separated by a ten-year period--the first included patients observed from 1970 to 1976 and the second from 1988 to 1998. In the first series (20 patients), IE occurred mainly in patients with previous cardiac valvular lesion, the course was subacute and Streptococcus viridans was the predominant agent. In the last series (65 patients), most of the patients were young and had no previous valvular lesions. Right side endocarditis predominated and the course was acute. Most of patients were drug addicts and had HIV infection. Staphylococcus aureus was the predominant agent. The ages of the two series were significantly different (p < 0.005). The diagnostic value of transthoracic and transesophageal echocardiography is stressed. The details of the evolution of patients with HIV infection are presented according to the values of CD4+ lymphocyte counts. The relatively good prognosis of IE in drug addicts with antibiotic treatment, even with HIV infection, is emphasized.

Adult↗

[Hearing loss and human immunodeficiency virus infection. Study of 30 patients].

OBJECTIVE: To asses hearing loss in patients infected with the human immunodeficiency virus (HIV) and its relationship with clinical stage (fulfillment of diagnostic criteria for human acquired immunodeficiency syndrome/AIDS) and degree of lymphocyte depletion (number of CD4+ lymphocytes). METHODS: Assessment of thirty consecutive HIV-infected patients regarding the presence of subjective hearing loss, pure-tone audiometry, brain stem auditory evoked potentials (BAEP); and number of CD4+ lymphocytes and treatment with antiretroviral drugs. RESULTS: Forty percent of patients reported hearing loss; 33% had an abnormal audiometry and BAEPs were abnormal in 56% of patients. The most common findings included high-frequency sensorineural loss and an increase in the wave III latency and interaural I-V difference. Subjective hearing loss and an abnormal audiometry were both related to the administration of antiretroviral drugs, whereas abnormal BAEPs were related to AIDS and low CD4+ lymphocyte counts. CONCLUSIONS: In HIV infected patients, an abnormal BAEP is the most common audiologic disorder, particularly in the advanced stages of the disease.

Adult↗

Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection.

OBJECTIVES: To determine rates of drug resistance to Mycobacterium tuberculosis and associated risk factors, including HIV infection. DESIGN: Prospective cohort study of patients with pulmonary tuberculosis. SETTING: The study population comprised 28,522 men working on four goldmines in Westonaria, Gauteng. Health care is provided at a 240-bed mine hospital, Gold Fields West Hospital, and its primary health care facilities. SUBJECTS: All 425 patients with culture-positive pulmonary tuberculosis identified in 1995. OUTCOME MEASURES: Tuberculosis drug resistance on enrollment and after 6 months' treatment. RESULTS: There were 292 cases of new tuberculosis, 77 of recurrent disease and 56 prevalent cases in treatment failure. Two hundred and seven patients (48.7%) were HIV infected. Primary resistance to one or more drugs (9%) was similar to the 11% found in a previous study done on goldminers in 1989. Primary multidrug resistance (0.3%) was also similar (0.8%). Acquired multidrug resistance was 18.1%: 6.5% for recurrent disease and 33.9% in treatment failure cases. Neither HIV infection nor the degree of immunosuppression as assessed by CD4+ lymphocyte counts was associated with drug resistance at the start or end of treatment. New patterns of drug resistance were present in 9 of 52 patients in treatment failure at 6 months, 1 of whom was HIV-infected. CONCLUSION: Primary and acquired drug resistance rates are stable in this population and are not affected by the high prevalence of HIV infection.

AIDS-Related Opportunistic Infections↗

Evolving characteristics of AIDS-related lymphoma.

Over time, the epidemiologic and demographic characteristics of AIDS have changed in the United States, while the use of highly active antiretroviral therapy has changed the natural history of the disease. The goal of the study was to ascertain any changes in the epidemiologic, immunologic, pathologic, or clinical characteristics of AIDS-related lymphoma (ARL) over the course of the AIDS epidemic. Records of 369 patients with ARL diagnosed or treated at a single institution from 1982 through 1998 were reviewed. Single institutional data were compared to population-based data from the County of Los Angeles. Significant changes in the demographic profile of patients with newly diagnosed ARL have occurred, with the later time intervals associated with a higher prevalence in women (P =.25), in Latino/Hispanic individuals (P <.0001), and in those who acquired human immunodeficiency virus (HIV) heterosexually (P =.01). These changes were similar in both countywide, population-based analyses and in those from the single institution. The median CD4(+) lymphocyte count at lymphoma diagnosis has decreased significantly over the years, from 177/dL in the earliest time period (1982-1986), to 53/dL in the last time period from 1995 to 1998 (P =.0006). The pathologic spectrum of disease has also changed, with a decrease in the prevalence of small noncleaved lymphoma (P =.0005) and an increase in diffuse large cell lymphoma (P <.0001). Despite changes in the use of antiretroviral or chemotherapy regimens, the median survival has not significantly changed.

AIDS-Related Opportunistic Infections↗

Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.

There is a high prevalence of cytomegalovirus (CMV) infection in the general population. An important proportion of immunodepressed patients are latent carriers of the virus, and under these conditions, the lack of cellular immunity predisposes the patient to an active infection in which the virus is replicating. Consequences for the immunodepressed patients are widely variable, ranging from completely asymptomatic infections to life-threatening situations. An important characteristic of these infections is that they have no specific clinical symptoms and are often indistinguishable from other types of infection. As such, clinical diagnosis should be supported by laboratory tests. There are many diagnostic tests available, the choice of which one to use being made on the basis of clinician-defined objectives. The CMV immunological state of the patient should be ascertained in order to indicate the possibility of reactivation or the risk of primary infection. To this end, serological tests have proven to be the most useful. Laboratory tests also allow the rapid diagnosis of active CMV infections, for which rapid culture techniques (shell-vial) or viral antigen tests (antigenemia pp65) are more appropriate. Given that not all active infections present with symptoms, the most typical problem in clinical practice is to distinguish between symptoms and illnesses caused by CMV (CMV disease: CMVD), and other infectious or non-infectious entities. To clarify this situation, diagnostic histopathology and methods able to quantify the viral load (pp65 antigenemia and quantitative PCR) are of great use. The identification of patients who, during active infection, are at high risk of contracting CMVD in the near future, is a more complex challenge for the laboratory. Once again, tests that are able to quantify the viral load are the most appropriate for identifying those patients who should receive preventive antiviral treatment. In HIV-positive patients, CMVD tends to manifest itself as retinitis and involvement of the gastrointestinal tract. The principal risk factor in the development of CMVD in these patients is the degree of immunodepression, which appears almost exclusively in patients with a CD4+ lymphocyte count lower than 50/mm3 and when other opportunistic infections have occurred. The advent of oral ganciclovir has raised the possibility of long-term prophylactic treatment of CMVD, making the search for virological and immunological markers that identify these high-risk patients a priority. Techniques allowing the quantification of CMV viremia, namely pp65 antigenemia and quantitative PCR, have been most useful to this end.

AIDS-Related Opportunistic Infections↗

[Clinical course of cytomegalovirus retinitis with the different antiretroviral therapies in our hospital].

PURPOSE: A study of protease inhibitors on CMV retinitis in HIV infected hospital patients. METHOD: A retrospective study was performed in 485 diagnosed of AIDS, between January, 1990 and December 1998. Among those, 81 patients who were diagnosed of CMV retinitis, the following was studied: anti-retroviral treatment, anti CMV treatment, survival time and CD4 lymphocyte count. RESULTS: Treatment with protease inhibitors in HIV patients showed an increase in life expectancy, reduced the incidence of CMV retinitis and a reduction in CMV retinitis prevention treatment was observed. CONCLUSIONS: Treatment with protease inhibitors has reduced the rate of CMV retinitis in HIV patients.

Acquired Immunodeficiency Syndrome↗

[Study of cases of HIV infection in Castile-Leon prisons].

OBJECTIVE: To study the HIV infection cases among inmates in Castile-León prisons and the therapy status and clinical follow-up. MATERIALS Y METHODS: The socio-demographic, clinical and virological parameters were studied of all seropositive inmates of seven out of eight prisons in Castile-León. A personal survey and a review of the medical records were conducted. RESULTS: A total of 413 HIV infected inmates were detected (12.05% out of 3,426 inmates); 98.6% were males, mostly of them caucasians. Parenteral drug abuse accounted for most infections (94.9%). Co-infection with hepatitis C virus was present in 81.4%, whereas the presence of surface antigen of the hepatitis B virus was detected in 12.6%. The median of CD4 lymphocyte count was 426.5 (interquartile range: 264.25 to 598.50) and of viral load 3.69 logs of particles/ml (interquartile range: 2.18 to 4.45). A total of 171 individuals are on anti-retroviral therapy, most of them with triple therapy; 40.4% of them had a viral load below 400 copies/ml. Over one third of seropositive individuals (37.3%) required therapy and are not on therapy, either because they have not initiated therapy or because of non-compliance. CONCLUSIONS: A highly representative study of the area which reveals a low number of identified seropositive individuals, mainly in association with drug abuse. The therapeutic guidelines are the standards but there is a high percentage of individuals requiring therapy. Co-infection with hepatitis C virus is extremely high, which will undoubtedly pose new therapeutic approaches.

Adult↗

Management of HIV-infected adults: antiretroviral treatment.

(1) The main aim of antiretroviral therapy is to inhibit viral replication as fully and as durably as possible. The reference treatment is currently a regimen combining three antiretroviral drugs belonging to two different classes. (2) Viral load and the CD4+ lymphocyte count are the best available markers for follow-up and decision-making. (3) Viral resistance, along with frequent cross-resistance within a given class of antiretroviral drugs, limits the therapeutic options. (4) Adherence to treatment is of major importance. Prescription of antiretroviral drugs must be part of a "treatment plan" decided with and accepted by the patient. (5) First-line treatment and subsequent modifications are based mainly on viral load values. A confirmed rebound of viral replication necessitates a rapid switch in treatment. (6) Viral load rebounds should be managed with antiretroviral drugs that the patient has not yet received and to which no cross-resistance is expected. (7) After repeated treatment failure, T cell counts are more useful and important than viral load values. It may be better to continue the ongoing treatment unchanged than to partially modify it. (8) Treatment success depends partly on the patient's social environment and quality of care.

Adult↗

Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance.

(1) The reference antiretroviral treatment for HIV-infected patients is a three-drug regimen combining drugs from different families, namely two nucleoside reverse transcriptase inhibitors + a protease inhibitor or a non nucleoside reverse transcriptase inhibitor. In our opinion, indinavir is the first-choice protease inhibitor. (2) The clinical file on amprenavir is limited. In particular, it is not known whether the recommended dose regimen (1 200 mg twice a day) is the best one. A 48-week trial involving 232 patients previously untreated with antiretrovirals showed that the combination of amprenavir (1 200 mg) + lamivudine (150 mg) + zidovudine (300 mg), administered twice a day, was more effective than lamivudine + zidovudine on viral load. (3) An unblinded trial involving 504 patients, who had already received a reverse transcriptase inhibitor but no protease inhibitor, compared three-drug regimens consisting of amprenavir (1 200 mg twice a day) and two reverse transcriptase inhibitors, or indinavir (800 mg three times a day) and two reverse transcriptase inhibitors, for 48 weeks. Changes in viral load and the CD4+ lymphocyte count did not favour the amprenavir-containing regimen. (4) Laboratory studies suggest that the risk of cross-resistance between amprenavir and other HIV protease inhibitors is lower than with other compounds of this class. However, it is unclear whether this means that amprenavir would be clinically effective after failure of one or several other protease inhibitors. (5) The main adverse effects of amprenavir are gastrointestinal disorders and paraesthesias. Overall, the safety profile resembles that of the other protease inhibitors. (6) Like other protease inhibitors, amprenavir can potentially interact with many other drugs, owing to its hepatic metabolism. (7) Amprenavir is taken in two daily doses irrespective of meal times, but this advantage over other protease inhibitors is cancelled out by the fact that patients have to swallow 8 large soft capsules at each intake. (8) In our opinion, pending further data, amprenavir should be used only in well-conducted clinical trials.

Anti-Infective Agents↗

Filgrastim: new indication. AIDS-associated neutropenia: another soft indication.

(1) Neutropenia is frequent in patients with AIDS and is an added risk factor for infection. There is no specific treatment, except, when feasible, the withdrawal of a suspected culprit drug. (2) Filgrastim, a granulocyte growth factor, has been granted a license extension to cover the treatment of persistent neutropenia in patients at an advanced stage of HIV infection. (3) Only one comparative, unblinded trial has been published in this setting. It involved 258 patients distributed into three groups, who received daily filgrastim, intermittent filgrastim, or no treatment. Six months after the beginning of the trial, filgrastim had not reduced the number of deaths, the number of hospital days, or the risk of bacterial or fungal infection. (4) The trial report fails to show whether filgrastim influences viral load or the CD4+ lymphocyte count. (5) In the absence of published dose-finding studies there is no proof that the dose regimen recommended in the licensing terms is the one with the best risk-benefit ratio. (6) Treatment with filgrastim is costly, especially as the available unit doses are unsuitable for this indication. (7) Patients at an advanced stage of HIV infection are already heavily medicated. There is no reason to add filgrastim, which has no proven clinical value.

Acquired Immunodeficiency Syndrome↗